Scpharmaceuticals Inc (NASDAQ: SCPH) recently announced highly statistically significant positive results from its FREEDOM-HF clinical trial, aimed at evaluating overall and heart-failure-related treatment costs for congestion in patients with chronic heart failure (CHF). Patients were treated with the company’s investigational subcutaneous furosemide injection product, FUROSCIX®, post-discharge from the emergency department. […]